Rockefeller Capital Management
SPRO icon

Rockefeller Capital Management’s Spero Therapeutics SPRO Stock Holding History

Rockefeller Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$466 – 4862
2025
Q4 		$466 Hold
200
– – ﹤0.01% 4536
2025
Q3 		$376 Buy
+200
New +$440 ﹤0.01% 4306
2021
Q3 		– Sell
-10
Closed – – 3840
2021
Q2 		$0 Hold
10
– – ﹤0.01% 3595
2021
Q1 		$0 Buy
+10
New +$176 ﹤0.01% 3380

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Rockefeller Capital Management's SPRO Position: Q1 2026 in Review

Rockefeller Capital Management sold out of Spero Therapeutics (SPRO) in Q1 2026, closing a stake of 200 shares — an estimated $466 sold.

Rockefeller Capital Management first reported a position in SPRO in Q1 2021 and held it in 4 quarters. The position peaked at $466 in Q4 2025. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Rockefeller Capital Management reported no remaining Spero Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Rockefeller Capital Management sold 200 Spero Therapeutics shares in Q1 2026, an estimated $466.
  • Rockefeller Capital Management first reported a position in Spero Therapeutics in Q1 2021 and held it in 4 quarters.
  • Rockefeller Capital Management's Spero Therapeutics position peaked at $466 in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.